Privacy, Policy and Legal Issues > Current Policy Priority

Current Policy Priority

Reducing Hereditary Cancer Act

Insurance Coverage & Barriers

Expand Medicare beneficiary access to genetic counseling, testing, cancer screening & prevention

            ACT NOW - Email your members of Congress to support this important bill

February 16, 2022 - Introduced today in the U.S. Senate, the Reducing Hereditary Cancer Act (S.3656) is bipartisan legislation that aims to modify the Medicare statutes to enable coverage of potentially life-saving genetic counseling, testing, screening and risk-reducing interventions. A companion bill, H.R.4110, was introduced in the U.S. House in June.

Under the existing Medicare guidelines, only a person with “signs, symptoms, complaints, or personal histories of disease” meets the criteria for coverage of medical services. Recognizing the value of cancer prevention and early detection, in recent years Congress has passed legislation allowing for coverage of cancer screenings (e.g., mammograms, colonoscopies and PSA tests) for the “average risk” population, and specific screenings (e.g. colonoscopies every 2 years) for some people considered high-risk. Unfortunately, many guideline-recommended screenings and risk-reduction measures needed by individuals at increased risk of cancer are not covered.

Medicare covers genetic testing only for beneficiaries already diagnosed with cancer, regardless of family cancer history or a known genetic mutation in the family. If someone without cancer learns they have one of these mutations (a previvor), many medically necessary cancer screenings or risk-reducing surgeries are not covered by Medicare.

With the availability of low-cost genetic testing, a growing number of Medicare beneficiaries learn that they have an inherited genetic mutation that significantly increases their risk of cancer but they aren’t able to access the health services they need to prevent or detect cancer earlier, when it is easier and less expensive to treat. As a result, they face a dilemma: forgo the expert-recommended screenings and interventions or shoulder the cost for tests such as annual breast MRIs, or risk-reducing surgery such as hysterectomy.

Importantly, most people with private insurance do not face the same obstacle. We must prioritize screening, early detection, and prevention in all communities and age groups—and focus on policies that reduce barriers for vulnerable populations.

As recommended by National Comprehensive Cancer Network (NCCN) or similar medical guidelines, it will enable coverage of genetic counseling and testing for Medicare beneficiaries with a:

  • Family history of a hereditary cancer gene mutation, or
  • Personal or family history suspicious for hereditary cancer

For Medicare beneficiaries who have an inherited genetic mutation causing an increased risk of cancer, the law will enable coverage of guideline-recommended:

  • Increased cancer screenings (e.g. breast MRI, upper endoscopy)
  • Risk-reducing surgeries (e.g. removal of ovaries and fallopian tubes)

TAKE ACTION - email your senators and member of Congress to support this important bill

See below for additional information and resources related to this important legislation!

We would like to thank the bill co-leaders for their commitment and support.

U.S. House of Representatives - Debbie Wasserman Schultz (D-FL), Mariannette Miller-Meeks (R-IA), Rodney Davis (R-IL), Elissa Slotkin (D-MI)

U.S. Senate - Lisa Murkowski (R-AK) and Ben Cardin (D-MD)

Take Action Now 2022 Priorities Advocacy Archive Public Policy Initiatives

News Briefs

5/22/2022 - Provided feedback to the Senate HELP Committee urging changes to the VALID Act, which would reform the way lab tests are regulated. This followed a sign-on letter regarding the bill submitted the previous week.

4/25/2022 - FORCE added its support to an effort spearheaded by SNMMI asking the House Energy and Commerce and Ways and Means Committee Leadership to schedule a hearing on the Facilitating Innovative Nuclear Diagnostics (FIND) Act. 

4/5/2022 - Joined a coalition letter to the HHS Secretary emphasizing that regulatory reform of the framework for clinical laboratory diagnostics is essential to protect patients and ensure access to innovative, high-quality diagnostic tests.


Key Facts Key Facts

  • Inherited genetic mutations (BRCA, ATM, CHEK2, PALB2, Lynch syndrome, etc.) are associated with an increased risk for a number of malignancies, including breast, colorectal, prostate, pancreatic, ovarian, stomach, and endometrial cancers.
  • Up to 10% of all cancers are due to a cancer-related genetic mutation; that number is significantly higher for certain cancers like ovarian, where nearly 25% of cases are due to an inherited mutation.
  • The more prevalent cancer-related genetic mutations are found in approximately one in every 300 Americans, with certain populations and ethnicities having higher rates.